BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.
Rhea-AI Summary
BrainsWay (NASDAQ & TASE: BWAY) announced a strategic minority-stake equity financing in Canadian provider BrainStim Health on Feb 19, 2026.
BrainsWay will invest an initial $1.0 million, with up to an additional $1.5 million via two milestone-based investments, in a preferred, annually compounding security; the deal includes a redemption mechanism and marks BrainsWay's fifth minority-stake clinical investment.
Positive
- None.
Negative
- None.
News Market Reaction – BWAY
On the day this news was published, BWAY declined 7.45%, reflecting a notable negative market reaction. Argus tracked a trough of -5.2% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $39M from the company's valuation, bringing the market cap to $487M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BWAY showed a 4.29% prior 24h gain, while peers were mixed: STIM down 2.82%, CATX up 4.14%, OM up 7.43% (also in momentum scanner at +1.15%), VMD up 0.72%, NNOX up 2.18%. This pattern points to a stock-specific narrative rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Coverage expansion | Positive | +4.3% | Evernorth removing prior authorization for TMS coverage across 12 states. |
| Feb 17 | Capital structure change | Positive | +8.6% | ADS-to-ordinary share ratio change, equivalent to 2-for-1 ADS forward split. |
| Jan 21 | Draft coverage policy | Positive | +4.7% | Highmark draft policy expanding coverage for accelerated Deep TMS SWIFT protocol. |
| Jan 12 | FDA approval | Positive | +4.7% | FDA PMA approval for Neurolief’s Proliv Rx neuromodulation system for MDD. |
| Jan 07 | Coverage policy | Positive | +3.6% | Premera coverage policy for accelerated SWIFT Deep TMS for MDD patients 15+. |
Recent coverage expansions, structural ADS changes, and strategic/regulatory milestones have all coincided with positive next-day price reactions.
Over the last few months, BrainsWay has reported several favorable developments: new and draft coverage policies for its accelerated Deep TMS protocol from major insurers, an ADS ratio change equivalent to a 2-for-1 forward split, and FDA PMA approval tied to its Neurolief investment. Each of these announcements led to positive 24-hour moves of between 3.56% and 8.61%. The new minority-stake investment in BrainStim continues this pattern of leveraging strategic partnerships and payor wins to broaden access to its technologies.
Market Pulse Summary
The stock moved -7.5% in the session following this news. A negative reaction despite another strategic partnership would contrast with BrainsWay’s recent history, where coverage, FDA, and investment updates produced 24-hour gains between 3.56% and 8.61%. A pullback could reflect concerns over capital allocation, integration, or returns from minority stakes. Investors may focus on how quickly BrainStim meets milestones and whether these small, compounding preferred positions materially enhance BrainsWay’s growth trajectory over time.
Key Terms
equity financing agreement financial
preferred financial
redemption mechanism financial
deep tms medical
dtms medical
AI-generated analysis. Not financial advice.
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care
BURLINGTON, Mass. and JERUSALEM, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with BrainStim Health Inc. (“BrainStim”), a provider based in British Columbia servicing a growing number of mental health clinics in Canada. Under the terms of the agreement, BrainsWay will invest
“Our investment in BrainStim is now the fifth minority-stake investment into growth-oriented clinical service platforms announced by the Company. These minority stake investments support our broader strategic initiative to expand access to and awareness of cutting-edge mental health interventions such as Deep TMS, while allowing BrainsWay to continue focusing on the scientific and clinical advancement of its technology, working to expand its range of cleared clinical indications, and delivering best-in-class support to all its customers,” said Hadar Levy, BrainsWay’s Chief Executive Officer.
“As a long-time BrainsWay partner and an advocate for their dTMS technology, we are incredibly excited to link arms as we accelerate the growth of BrainStim,” said Dr. Venu Karapeddy, BrainStim’s Chief Medical Officer. “Partnering with an interventional psychiatry pioneer like BrainsWay only serves to strengthen our value proposition and increase our success. We look forward to this exciting chapter of organization growth and fulfilling our mission of delivering life-changing care at scale.”
Advocates Ami Hordes and Sarit Molcho of S. Friedman, Abramson & Co. Law Offices served as lead counsel for BrainsWay on the transaction with BrainStim as well as on the Company’s prior minority stake investments.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
About BrainStim
BrainStim is an interventional psychiatry practice focused on delivering the most effective mental health protocols for conditions, including severe trauma, stress, anxiety, and depression, especially for veterans and first responders. With a team of board-certified psychiatrists, advanced psychiatric nurse practitioners, and patient care coordinators, BrainStim offers the most cutting-edge treatment options to treat the complex needs of patients. For more information, please visit BrainStim | Advanced Mental Health Treatments for Families & Veterans.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com
FAQ
What did BrainsWay (BWAY) announce on February 19, 2026 regarding BrainStim Health?
How much will BrainsWay (BWAY) invest initially in BrainStim Health and are there follow-on payments?
What form of security is BrainsWay (BWAY) using for its investment in BrainStim Health?
How does this BrainStim investment fit BrainsWay's (BWAY) broader strategy?
Who represented BrainsWay (BWAY) legally on the BrainStim transaction announced February 19, 2026?
